{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:06:25Z","timestamp":1785744385506,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.lungcan.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T21:16:55Z","timestamp":1645651015000},"page":"114-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study"],"prefix":"10.1016","volume":"166","author":[{"given":"Florian","family":"Slimano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Le Bozec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Cransac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Foucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lesauvage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Delclaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Mennecier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Gubeno-Dumon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Mongaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Hettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Boulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dewolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukshe","family":"Kanagaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.02.007_b0005","unstructured":"ALIMTA: Summary of Product Characteristics [online]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alimta-epar-product-information_en.pdf (Accessed: September 2, 2021)."},{"issue":"3","key":"10.1016\/j.lungcan.2022.02.007_b0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.lungcan.2022.02.007_b0015","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.lungcan.2022.02.007_b0020","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.lungcan.2022.02.007_b0025","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.lungcan.2022.02.007_b0030","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO.19.02674","article-title":"Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.lungcan.2022.02.007_b0035","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10026","key":"10.1016\/j.lungcan.2022.02.007_b0040","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.lungcan.2022.02.007_b0045","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.007_b0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/1120009X.2019.1572287","article-title":"Severe toxicity in adult patients with lung cancer under treatment with pemetrexed: a prospective cohort study","volume":"31","author":"V\u00e1zquez","year":"2019","journal-title":"J Chemother"},{"issue":"8 Suppl","key":"10.1016\/j.lungcan.2022.02.007_b0055","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/cncr.11279","article-title":"Review of a promising new agent\u2013pemetrexed disodium","volume":"97","author":"Paz-Ares","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2022.02.007_b0060","year":"2021","journal-title":"Available on"},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.007_b0065","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.lungcan.2022.02.007_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107647","article-title":"Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination","volume":"217","author":"Zhang","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.lungcan.2022.02.007_b0075","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/cpt.1360","article-title":"Clinical Aspects of Transporter-Mediated Drug-Drug Interactions","volume":"105","author":"Gessner","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.007_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11096-019-00958-5","article-title":"Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis","volume":"42","author":"Wang","year":"2020","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.007_b0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI114165","article-title":"Active proton secretion and potassium absorption in the rabbit outer medullary collecting duct. Functional evidence for proton-potassium-activated adenosine triphosphatase","volume":"84","author":"Wingo","year":"1989","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.007_b0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00686028","article-title":"Impact of omeprazole on the plasma clearance of methotrexate","volume":"33","author":"Reid","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.lungcan.2022.02.007_b0095","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1345\/aph.19094","article-title":"Potential interaction between methotrexate and omeprazole","volume":"34","author":"Beorlegui","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"16","key":"10.1016\/j.lungcan.2022.02.007_b0100","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1158\/0008-5472.CAN-03-4062","article-title":"Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions","volume":"64","author":"Breedveld","year":"2004","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.lungcan.2022.02.007_b0105","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1124\/dmd.114.058529","article-title":"Proton pump inhibitors inhibit methotrexate transport by renal basolateral organic anion transporter hOAT3","volume":"42","author":"Chioukh","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.007_b0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2133\/dmpk.DMPK-13-RG-042","article-title":"Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3","volume":"29","author":"Kurata","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"10","key":"10.1016\/j.lungcan.2022.02.007_b0115","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.116.070722","article-title":"Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3","volume":"44","author":"Ikemura","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.007_b0120","first-page":"276","article-title":"Effects of proton pump inhibitors on severe haematotoxicity induced after first course of pemetrexed\/carboplatin combination chemotherapy","volume":"44","author":"Araki","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.lungcan.2022.02.007_b0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2022.02.007_b0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10254-002-0003-8","article-title":"Transport of organic anions across the basolateral membrane of proximal tubule cells","volume":"146","author":"Burckhardt","year":"2003","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.007_b0135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by Organic Anion Transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.lungcan.2022.02.007_b0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejps.2017.11.001","article-title":"Renal organic anion transporters in drug-drug interactions and diseases","volume":"112","author":"Huo","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"10.1016\/j.lungcan.2022.02.007_b0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.007_b0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/1078-0432.CCR-05-1834","article-title":"Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer","volume":"12","author":"Sweeney","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lungcan.2022.02.007_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171066","article-title":"Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study","volume":"12","author":"Kawazoe","year":"2017","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.lungcan.2022.02.007_b0160","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.lungcan.2022.02.007_b0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13739","article-title":"Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer","volume":"4","author":"Raoul","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lungcan.2022.02.007_b0170","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.007_b0175","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.cllc.2017.04.003","article-title":"Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies","volume":"18","author":"Langer","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.02.007_b0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"de Rouw","year":"2020","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2022.02.007_b0185","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/JTO.0000000000000207","article-title":"Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study","volume":"9","author":"Gridelli","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2022.02.007_b0190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejps.2014.04.004","article-title":"Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans","volume":"59","author":"Maeda","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1016\/j.lungcan.2022.02.007_b0195","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1248\/bpb.b15-00162","article-title":"Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer","volume":"38","author":"Ikesue","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.lungcan.2022.02.007_b0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s40800-018-0093-0","article-title":"Neutropenia and Thrombocytopenia Induced by Proton Pump Inhibitors: A Case Report","volume":"5","author":"Yu","year":"2018","journal-title":"Drug Saf Case Rep"},{"issue":"8","key":"10.1016\/j.lungcan.2022.02.007_b0205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/11537230-000000000-00000","article-title":"Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole","volume":"30","author":"Gouraud","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.lungcan.2022.02.007_b0210","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.11.5.809","article-title":"Effect of probenecid on the blood levels and urinary excretion of cefamandole","volume":"11","author":"Griffith","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lungcan.2022.02.007_b0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-642-14541-4_2","article-title":"In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy","volume":"201","author":"Burckhardt","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"9","key":"10.1016\/j.lungcan.2022.02.007_b0220","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/bdd.2091","article-title":"Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3","volume":"38","author":"Narumi","year":"2017","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"10.1016\/j.lungcan.2022.02.007_b0225","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.revmed.2020.11.014","article-title":"Evaluation of the implantation of a de-prescribing process for proton pump inhibitor (PPI) using an algorithm within an internal medicine department","volume":"42","author":"Valette","year":"2021","journal-title":"Rev Med Interne"},{"issue":"8","key":"10.1016\/j.lungcan.2022.02.007_b0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161248","article-title":"Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing","volume":"11","author":"Farrell","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.lungcan.2022.02.007_b0235","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s002280100342","article-title":"Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism","volume":"57","author":"Ieiri","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.lungcan.2022.02.007_b0240","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00216-013-7560-3","article-title":"A fluorescence-based high throughput assay for the determination of small molecule-human serum albumin protein binding","volume":"406","author":"McCallum","year":"2014","journal-title":"Anal Bioanal Chem"},{"issue":"11","key":"10.1016\/j.lungcan.2022.02.007_b0245","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3109\/00498254.2012.687119","article-title":"Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects","volume":"42","author":"Zhang","year":"2012","journal-title":"Xenobiotica"},{"issue":"9","key":"10.1016\/j.lungcan.2022.02.007_b0250","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/pharmaceutics12090846","article-title":"Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice","volume":"12","author":"Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.lungcan.2022.02.007_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2022.02.007_b0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2019.08.012","article-title":"Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study","volume":"121","author":"Visser","year":"2019","journal-title":"Eur J Cancer."},{"issue":"3","key":"10.1016\/j.lungcan.2022.02.007_b0265","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-015-2954-x","article-title":"Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy","volume":"77","author":"Takagi","year":"2016","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222003634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222003634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:01:13Z","timestamp":1759237273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222003634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":53,"alternative-id":["S0169500222003634"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.02.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}